Ponoi II Management, LLC
Follow13F filer, CIK 1746488, San Francisco, CA
Ponoi II Management, LLC reported $55,057,000 across 4 holdings for the quarter ended 2021-12-31, in a 13F-HR filed 2022-02-11.
Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000950123-22-002170
- Period
- 2021-12-31
- Reported value
- $55.1M
- Holdings
- 4
- Top 10 weight
- 100%
- New
- 0
- Sold out
- 0
Largest buys vs the previous quarter
None.
Largest sells vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| NRIXreduced | -234,451 | -$6.79M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Holdings, Q4 2021
Share positions as resolved from 13F-HR 0000950123-22-002170, largest first. % of portfolio is the value over $55,057,000, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| NGM BIOPHARMACEUTICALS INCNGM BIOPHARMACEUTICALS INC | 1,298,908 | $23M | 41.78% | 0 | |||
| RVMDREVOLUTION MEDICINES INC | 685,011 | $17.2M | 31.32% | 0 | Timeline | ||
| NRIXNURIX THERAPEUTICS INC | 327,123 | $9.47M | 17.2% | -234,451 | Timeline | ||
| RAPT THERAPEUTICS INCRAPT THERAPEUTICS INC | 145,401 | $5.34M | 9.7% | 0 |
How Q4 2021 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0000950123-22-002170 | base | 2022-02-11 | acceptance time not in the bulk data set |